Actions of N-arachidonyl-glycine in a rat inflammatory pain model

• Main Authors: Vaughan Christopher W, Mitchell Vanessa A, Succar Rebecca
• Format: Article
• Language: English
• Published: SAGE Publishing 2007-08-01
• Series: Molecular Pain
• Online Access: http://www.molecularpain.com/content/3/1/24

<p>Abstract</p> <p>Background</p> <p>While cannabinoid receptor agonists have analgesic activity in inflammatory pain states they produce a range of side effects. Recently, it has been demonstrated that the arachidonic acid-amino acid conjugate, N-arachidonyl-glycine (NA-glycine) is effective in acute pain models.</p> <p>Results</p> <p>In the present study we examined the effect of NA-glycine in a rat model of inflammatory pain. Intrathecal administration of NA-glycine (70 – 700 nmol) and the pan-cannabinoid receptor agonist HU-210 (10 nmol) reduced the mechanical allodynia and thermal hyperalgesia induced by intraplantar injection of Freund's complete adjuvant (FCA). The actions of HU-210, but not NA-glycine were reduced by the cannabinoid CB₁receptor antagonist AM251. The cannabinoid CB₂receptor antagonist SR144528 also had no effect on the actions of NA-glycine. In contrast, N-arachidonyl-GABA (NA-GABA, 700 nmol) and N-arachidonyl-alanine (NA-alanine, 700 nmol) had no effect on allodynia and hyperalgesia. HU-210, but not NA-glycine produced a reduction in rotarod latency.</p> <p>Conclusion</p> <p>These findings suggest that NA-glycine may provide a novel non-cannabinoid receptor mediated approach to alleviate inflammatory pain.</p>